| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 9,040 | 9,300 | 07:00 |
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 02.10. | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 02.10.2026 -4- | 2.320 | Xetra Newsboard | The following instruments on Boerse Frankfurt do have their last trading day on 02.10.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 02.10.2026ISIN NameUS1509643029 CENNTRO... ► Artikel lesen | |
| ENVVENO MEDICAL Aktie jetzt für 0€ handeln | |||||
| 02.10. | enVVeno Medical Corporation: enVVeno Medical's First-in-Class enVVe System to Be Featured at The VEINS 2026 Innovation Summit as Company Advances Toward U.S. Pivotal Trial | 726 | ACCESS Newswire | Leading venous interventionalist Karen B. Garby, MD, DABVLM, RPhS, to present the enVVe System, a minimally invasive replacement venous valve currently being evaluated in a U.S. pivotal studyAn estimated... ► Artikel lesen | |
| 16.09. | enVVeno Medical Corporation: enVVeno Medical CEO Rob Berman Goes Direct to Investors with New "WTF" Video Series | 419 | ACCESS Newswire | New CEO-led video series provides investors with straight talk, just the facts, with no B.S. or corporate spinReal answers to what investors need to know about enVVeno and why they need to know itWatch... ► Artikel lesen | |
| 11.09. | enVVeno Medical Corporation: enVVeno Medical Presentation from H.C. Wainwright Conference Now Available On-Demand | 367 | ACCESS Newswire | Access the video webcast here IRVINE, CA / ACCESS Newswire / September 11, 2026 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno Medical" or the "Company"), today announced that its pre-recorded... ► Artikel lesen | |
| 27.08. | enVVeno Medical Corporation: enVVeno Medical Participates in the Virtual Investor 'Why Now' On-Demand Conference | 469 | ACCESS Newswire | Video Webcast Now Available Here IRVINE, CA / ACCESS Newswire / August 27, 2026 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno Medical" or the "Company") today announced that Robert Berman, Chief... ► Artikel lesen | |
| 04.08. | enVVeno Medical Corporation: Independent Health Economic Study Recently Published in Journal of Vascular Surgery Reports Economic Dominance of enVVeno Medical's Replacement Venous Valve Therapy Compared to Standard of Care Treatments | 475 | ACCESS Newswire | Published economic health study shows both short- and long-term cost-effectiveness of replacement venous value therapy versus standard-of-care treatments for deep venous CVI, generating compelling evidence... ► Artikel lesen | |
| 31.07. | enVVeno Medical wins FDA IDE for non-surgical transcatheter replacement venous valve | 1 | MassDevice | ||
| 31.07. | enVVeno Medical erhält FDA-Zulassung für zulassungsrelevante Studie | 2 | Investing.com Deutsch | ||
| 31.07. | enVVeno Medical GAAP EPS of -$5.37 misses by $2.10 | 2 | Seeking Alpha | ||
| 31.07. | enVVeno Medical Corporation: enVVeno Medical Reports Second Quarter 2026 Financial Results and Advances Towards FDA Pivotal Trial for First-in-Class Non-Surgical Replacement Venous Valve | 540 | ACCESS Newswire | Company Enters the Second Half of 2026 With Tailwinds From an FDA IDE Approval, With the TAVVE Pivotal Study Expected to Begin Enrolling Patients During the Second Half of This Year and Cash Runway... ► Artikel lesen | |
| 30.07. | enVVeno Medical Corp - 10-Q, Quarterly Report | 3 | SEC Filings | ||
| 15.07. | enVVeno Medical Corporation: enVVeno Medical Highlights Newly Issued U.S. Patent Strengthening Competitive Position Ahead of Historic Pivotal Trial in Virtual Investor "What This Means" Segment | 502 | ACCESS Newswire | CEO Explains How Broad Patent Protection, Combined with First-Ever FDA IDE Approval, Positions enVVe to Own a Multi-Billion-Dollar Venous Disease MarketWatch the "What This Means" video here IRVINE... ► Artikel lesen | |
| 14.07. | enVVeno Medical Corp - 8-K, Current Report | - | SEC Filings | ||
| 07.07. | enVVeno Medical receives U.S. patent for venous valve system | 2 | Investing.com | ||
| 07.07. | enVVeno Medical Corporation: enVVeno Medical Secures Transformational U.S. Patent for enVVe System, Strengthening Competitive Moat Ahead of Launch of Historic FDA Pivotal Trial | 834 | ACCESS Newswire | New Patent Broadly Protects Core Technology Behind Potential First Non-Surgical Replacement Venous Valve Builds on First-Ever FDA IDE Approval for Pivotal Study of enVVe System Targeting Multi-Billion-Dollar... ► Artikel lesen | |
| 22.06. | enVVeno Medical Corporation: enVVeno Medical to Present in the Webull Corporate Connect Webinar Series | 371 | ACCESS Newswire | - Live webcast on Wednesday, June 24th at 2:00 PM ET- Access the event here IRVINE, CA / ACCESS Newswire / June 22, 2026 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"),a company... ► Artikel lesen | |
| 02.06. | enVVeno Medical Corporation: enVVeno Medical to Participate in the Virtual Investor Closing Bell Series | 321 | ACCESS Newswire | Live video webcast with Robert Berman, Chief Executive Officer of enVVeno Medical, on Tuesday, June 9that 4:00 PM ETRegister here IRVINE, CA / ACCESS Newswire / June 2, 2026 / enVVeno Medical Corporation... ► Artikel lesen | |
| 12.05. | enVVeno Medical Corporation: enVVeno Medical Discusses FDA IDE Approval in Virtual Investor "What This Means" Segment | 563 | ACCESS Newswire | First-Ever FDA IDE Approval for a U.S. Pivotal Study of a Non-surgical Replacement Venous ValveIDE approval positions enVVeno to advance what could become the first effective treatment option for the... ► Artikel lesen | |
| 07.05. | enVVeno Medical GAAP EPS of -$5.89 | 3 | Seeking Alpha | ||
| 07.05. | enVVeno Medical Corporation: enVVeno Medical Reports First Quarter 2026 Financial Results and Provides Business Update Highlighting Strategic Advancement of the enVVe System | 839 | ACCESS Newswire | Company ended the first quarter with approximately $25 million in cash and investmentsCapital on hand should fund operations through multiple key milestones into Q3 2027Company recently received FDA... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| FRESENIUS MEDICAL CARE | 39,540 | +0,20 % | DEUTSCHE BANK RESEARCH stuft FMC FRESENIUS MEDICAL CARE AG auf 'Hold' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat Fresenius Medical Care (FMC) auf "Hold" mit einem Kursziel von 40 Euro belassen. Mit dem etwas überraschenden Führungswechsel gehe eine starke... ► Artikel lesen | |
| SIEMENS HEALTHINEERS | 41,450 | +1,47 % | EQS-CMS: Siemens Healthineers AG: Veröffentlichung einer Kapitalmarktinformation | EQS Zulassungsfolgepflichtmitteilung: Siemens Healthineers AG
/ Bekanntmachung nach Art. 5 Abs. 1 lit. b), Abs. 3 der Verordnung (EU) Nr. 596/2014, zuletzt geändert durch die Verordnung... ► Artikel lesen | |
| CARL ZEISS MEDITEC | 32,760 | +0,06 % | DEUTSCHE BANK RESEARCH stuft CARL ZEISS MEDITEC AG auf 'Hold' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat die Einstufung für Carl Zeiss Meditec vor Zahlen auf "Hold" mit einem Kursziel von 26 Euro belassen. Das Medizintechnik-Unternehmen dürfte ein... ► Artikel lesen | |
| ECKERT & ZIEGLER | 12,750 | +3,49 % | Eckert & Ziegler: Independence gains value: Recent radiopharma transactions highlight the strategic value of EUZ's independent ... | Recent radiopharma acquisitions underline the value of EUZ's core capabilities: independent isotope supply and specialist manufacturing. Strategic and financial investors are acquiring comparable isotope... ► Artikel lesen | |
| INTUITIVE SURGICAL | 381,45 | -0,04 % | Intuitive Surgical is Down this Year Despite Double-Digit Growth. Is Its 33x Valuation Still Justified? | ||
| MEDTRONIC | 84,70 | -1,01 % | 6,4 Millionen US-Dollar pro Patient: Warum Medtronic, Lifeward und NurExone an drei Stufen der Rückenmarksversorgung ansetzen | ||
| GERRESHEIMER | 30,440 | +6,06 % | EQS-PVR: Gerresheimer AG: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung | EQS Stimmrechtsmitteilung: Gerresheimer AG
Gerresheimer AG: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung
12.10.2026 / 17:29 CET/CEST
Veröffentlichung... ► Artikel lesen | |
| THERMO FISHER | 612,80 | -1,35 % | Dividendenbekanntmachungen (15.10.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ABBOTT LABORATORIES US0028241000 0,63 USD 0,5648 EUR ABBOTT LABORATORIES CDR CA0028221046 0,1096 CAD 0,069 EUR ABBVIE INC US00287Y1091 1... ► Artikel lesen | |
| TELADOC HEALTH | 5,168 | -2,86 % | Teladoc Health, Inc.: Teladoc Health to Announce Third Quarter 2026 Financial Results | ||
| STRATEC | 23,650 | -2,27 % | EQS-PVR: STRATEC SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution | EQS Voting Rights Announcement: STRATEC SE
STRATEC SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide... ► Artikel lesen | |
| RHOEN-KLINIKUM | 14,300 | -0,69 % | EQS-PVR: RHÖN-KLINIKUM AG: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung | EQS Stimmrechtsmitteilung: RHÖN-KLINIKUM Aktiengesellschaft
RHÖN-KLINIKUM AG: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung... ► Artikel lesen | |
| M1 AESTHETICS | 12,800 | -0,78 % | Dividendenbekanntmachungen (08.07.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) A2 MILK COMPANY LIMITED NZATME0002S8 0,4135 NZD 0,2059 EUR AGRANA BETEILIGUNGS-AG AT000AGRANA3 - 0,35 EUR BANK OF CHONGQING CO LTD CNE100001QN2 0... ► Artikel lesen | |
| EUROFINS SCIENTIFIC | 78,18 | -1,61 % | Eurofins Scientific SE: Eurofins Scientific: Director/PDMR Shareholding | Eurofins Scientific SE (EUFI.PA) (Paris:ERF) has received various notifications of dealing from Persons Discharging Managerial Responsibilities ("PDMR"). The notification of Dealing Form for each... ► Artikel lesen | |
| FRESENIUS | 45,075 | +2,78 % | VW und Autobauer im Fokus: DAX vor dem nächsten Schub? Diese Woche wird für Anleger entscheidend | © Foto: Boris Roessler/dpaDer DAX dürfte freundlich in die neue Woche starten. Auch die europäischen Futures liegen im Plus. Doch Öl, Inflation und die beginnende US-Berichtssaison könnten schnell für... ► Artikel lesen | |
| BRIGHTSPRING HEALTH SERVICES | 60,57 | -2,87 % | BrightSpring Health Services, Inc. Reports Second Quarter 2026 Financial Results and Increases Full Year 2026 Guidance | LOUISVILLE, Ky., July 31, 2026 (GLOBE NEWSWIRE) -- BrightSpring Health Services, Inc. ("BrightSpring" or the "Company") (NASDAQ: BTSG), a leading provider of home and community-based health services... ► Artikel lesen |